Weight loss surgery significantly lowers the risk of major adverse liver outcomes as well as major acute cardiovascular events (MACE) in patients with biopsy-proven nonalcoholic steatohepatitis (NASH), compared with similar patients who didn't have surgery, new research shows. "This is the first study in the medical field reporting a treatment modality that is associated with decreased risk of major adverse events in patients with biopsy-proven NASH," senior author Steven Nissen, MD. As the authors point out, obesity is the main pathophysiologic driver of NASH and weight loss — however achieved — is currently the primary treatment for NASH. "However, bariatric...